These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35247453)

  • 1. In vitro and in vivo pharmaco-dynamic study of the novel fentanyl derivatives: Acrylfentanyl, Ocfentanyl and Furanylfentanyl.
    Bilel S; Azevedo Neto J; Arfè R; Tirri M; Gaudio RM; Fantinati A; Bernardi T; Boccuto F; Marchetti B; Corli G; Serpelloni G; De-Giorgio F; Malfacini D; Trapella C; Calo' G; Marti M
    Neuropharmacology; 2022 May; 209():109020. PubMed ID: 35247453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances.
    Vandeputte MM; Cannaert A; Stove CP
    Arch Toxicol; 2020 Nov; 94(11):3819-3830. PubMed ID: 32734307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT
    Åstrand A; Guerrieri D; Vikingsson S; Kronstrand R; Green H
    Forensic Sci Int; 2020 Dec; 317():110553. PubMed ID: 33160102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensorimotor Alterations Induced by Novel Fentanyl Analogs in Mice: Possible Impact on Human Driving Performances.
    Bilel S; Giorgetti A; Tirri M; Arfè R; Cristofori V; Marchetti B; Corli G; Caruso L; Zauli G; Giorgetti R; Marti M
    Curr Neuropharmacol; 2023; 21(1):87-104. PubMed ID: 36397617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors.
    Varshneya NB; Walentiny DM; Moisa LT; Walker TD; Akinfiresoye LR; Beardsley PM
    Pharmacol Biochem Behav; 2021 Sep; 208():173242. PubMed ID: 34302853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of naloxegol: In vitro and in vivo studies.
    Costanzini A; Ruzza C; Neto JA; Sturaro C; Malfacini D; Sternini C; De Giorgio R; Calò G
    Eur J Pharmacol; 2021 Jul; 903():174132. PubMed ID: 33933466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
    Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
    Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Genotoxicity of Acrylfentanyl, Ocfentanyl and Furanylfentanyl Raises the Concern of Long-Term Consequences.
    Gasperini S; Bilel S; Cocchi V; Marti M; Lenzi M; Hrelia P
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH
    Gach-Janczak K; Piekielna-Ciesielska J; Adamska-Bartłomiejczyk A; Wtorek K; Ferrari F; Calo' G; Szymaszkiewicz A; Piasecka-Zelga J; Janecka A
    Peptides; 2018 Jul; 105():51-57. PubMed ID: 29684591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo pharmacological characterization of the synthetic opioid MT-45.
    Bilel S; Azevedo NJ; Arfè R; Tirri M; Gregori A; Serpelloni G; De-Giorgio F; Frisoni P; Neri M; Calò G; Marti M
    Neuropharmacology; 2020 Jul; 171():108110. PubMed ID: 32344007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.
    Mori T; Kuzumaki N; Arima T; Narita M; Tateishi R; Kondo T; Hamada Y; Kuwata H; Kawata M; Yamazaki M; Sugita K; Matsuzawa A; Baba K; Yamauchi T; Higashiyama K; Nonaka M; Miyano K; Uezono Y; Narita M
    Mol Pain; 2017; 13():1744806917740030. PubMed ID: 29056067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding preference at the μ-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl.
    Xie B; Le Rouzic VP; Goldberg A; Tsai MM; Chen L; Zhang T; Sinha A; Pan YX; Baumann MH; Shi L
    Neuropharmacology; 2023 Apr; 227():109442. PubMed ID: 36731721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.
    Podolsky AT; Sandweiss A; Hu J; Bilsky EJ; Cain JP; Kumirov VK; Lee YS; Hruby VJ; Vardanyan RS; Vanderah TW
    Life Sci; 2013 Dec; 93(25-26):1010-6. PubMed ID: 24084045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intoxications involving acrylfentanyl and other novel designer fentanyls - results from the Swedish STRIDA project.
    Helander A; Bäckberg M; Signell P; Beck O
    Clin Toxicol (Phila); 2017 Jul; 55(6):589-599. PubMed ID: 28349714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Opioid Analgesics for the Development of Transdermal Opioid Patches That Possess Morphine-Like Pharmacological Profiles Rather Than Fentanyl: Possible Opioid Switching Alternatives Among Patch Formula.
    Komatsu A; Miyano K; Nakayama D; Mizobuchi Y; Uezono E; Ohshima K; Karasawa Y; Kuroda Y; Nonaka M; Yamaguchi K; Iseki M; Uezono Y; Hayashida M
    Anesth Analg; 2022 May; 134(5):1082-1093. PubMed ID: 35427270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the μ-opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure.
    Åstrand A; Vikingsson S; Jakobsen I; Björn N; Kronstrand R; Gréen H
    Drug Test Anal; 2021 Jan; 13(1):169-174. PubMed ID: 32749741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and Structural Explorations of G-Protein Biased μ-Opioid Receptor Agonists.
    Li X; Guo Y; Li J; Yu Z; Cheng J; Ren F; Jia H; Zhang Y; Cui S; Zhang T; Shi W
    ChemMedChem; 2022 Dec; 17(24):e202200416. PubMed ID: 36210341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist.
    Rizzi A; Cerlesi MC; Ruzza C; Malfacini D; Ferrari F; Bianco S; Costa T; Guerrini R; Trapella C; Calo' G
    Pharmacol Res Perspect; 2016 Aug; 4(4):e00247. PubMed ID: 28116100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial versus full agonists for opioid-mediated analgesia--focus on fentanyl and buprenorphine.
    Zuurmond WW; Meert TF; Noorduin H
    Acta Anaesthesiol Belg; 2002; 53(3):193-201. PubMed ID: 12461829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the β-arrestin2 recruitment assay: No two ligands have the same profile.
    Kuo A; Magiera J; Rethwan N; Andersson Å; Leen Lam A; Wyse B; Meutermans W; Lewis R; Smith M
    Eur J Pharmacol; 2020 Apr; 872():172947. PubMed ID: 31991138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.